Clinical Trials Logo

Clinical Trial Summary

To Evaluate the Safety and Efficacy of Lonafarnib with and without Ritonavir Boosting in Adults With Genotype 1 Chronic Hepatitis D Virus (HDV) Infection (LOWR-1).


Clinical Trial Description

Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. Twenty-one subjects with chronic delta hepatitis will be randomized to receive one of seven different doses of lonafarnib. Dosing will occur over 4-12 weeks, depending on treatment arm, and during that time, evidence of antiviral response will be assessed by frequent measurements of HDV-RNA. The primary therapeutic endpoint will be an improvement in quantitative serum HDV RNA levels after treatment with lonafarnib therapy. The primary safety endpoint will be the ability to tolerate the drug at the prescribed dose for the treatment duration. Several secondary endpoints will be measured, including side effects, ALT levels, and symptoms. Therapy will be stopped for intolerance to lonafarnib. This study is designed as a phase 2a study assessing the safety, tolerance and antiviral activity of seven dose combinations of lonafarnib with and without ritonavir boosting. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02430181
Study type Interventional
Source Eiger BioPharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date November 2014
Completion date November 2015

See also
  Status Clinical Trial Phase
Completed NCT05827146 - Study of Hepalatide in Chronic Hepatitis D(CHD) Patients Phase 2
Recruiting NCT05760300 - A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function Phase 1
Recruiting NCT05765344 - Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function Phase 1
Recruiting NCT06248580 - Find HDV and Determine Its Status in Turkey
Recruiting NCT05718700 - Study of Bulevirtide in Participants With Chronic Hepatitis D Infection
Completed NCT02637999 - Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection Phase 1/Phase 2
Recruiting NCT04638439 - The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection Phase 1
Completed NCT02430194 - Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2) Phase 2